High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.
Prostate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of treatment. In this study, the potential of gene expression data and RNA interference technique were combined to advance future personalized prostate cancer therapeutics. To distinguish...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761906/pdf/?tool=EBI |
| _version_ | 1818401767594917888 |
|---|---|
| author | Paula Vainio John-Patrick Mpindi Pekka Kohonen Vidal Fey Tuomas Mirtti Kalle A Alanen Merja Perälä Olli Kallioniemi Kristiina Iljin |
| author_facet | Paula Vainio John-Patrick Mpindi Pekka Kohonen Vidal Fey Tuomas Mirtti Kalle A Alanen Merja Perälä Olli Kallioniemi Kristiina Iljin |
| author_sort | Paula Vainio |
| collection | DOAJ |
| description | Prostate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of treatment. In this study, the potential of gene expression data and RNA interference technique were combined to advance future personalized prostate cancer therapeutics. To distinguish the most promising in vivo prevalidated prostate cancer drug targets, a bioinformatic analysis was carried out using genome-wide gene expression data from 9873 human tissue samples. In total, 295 genes were selected for further functional studies in cultured prostate cancer cells due to their high mRNA expression in prostate, prostate cancer or in metastatic prostate cancer samples. Second, RNAi based cell viability assay was performed in VCaP and LNCaP prostate cancer cells. Based on the siRNA results, gene expression patterns in human tissues and novelty, endoplasmic reticulum function associated targets AIM1, ERGIC1 and TMED3, as well as mitosis regulating TPX2 were selected for further validation. AIM1, ERGIC1, and TPX2 were shown to be highly expressed especially in prostate cancer tissues, and high mRNA expression of ERGIC1 and TMED3 associated with AR and ERG oncogene expression. ERGIC1 silencing specifically regulated the proliferation of ERG oncogene positive prostate cancer cells and inhibited ERG mRNA expression in these cells, indicating that it is a potent drug target in ERG positive subgroup of prostate cancers. TPX2 expression associated with PSA failure and TPX2 silencing reduced PSA expression, indicating that TPX2 regulates androgen receptor mediated signaling. In conclusion, the combinatorial usage of microarray and RNAi techniques yielded in a large number of potential novel biomarkers and therapeutic targets, for future development of targeted and personalized approaches for prostate cancer management. |
| first_indexed | 2024-12-14T07:57:42Z |
| format | Article |
| id | doaj.art-ad04c72ed4ae49aca28665644374c670 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T07:57:42Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ad04c72ed4ae49aca28665644374c6702022-12-21T23:10:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0176e3980110.1371/journal.pone.0039801High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.Paula VainioJohn-Patrick MpindiPekka KohonenVidal FeyTuomas MirttiKalle A AlanenMerja PeräläOlli KallioniemiKristiina IljinProstate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of treatment. In this study, the potential of gene expression data and RNA interference technique were combined to advance future personalized prostate cancer therapeutics. To distinguish the most promising in vivo prevalidated prostate cancer drug targets, a bioinformatic analysis was carried out using genome-wide gene expression data from 9873 human tissue samples. In total, 295 genes were selected for further functional studies in cultured prostate cancer cells due to their high mRNA expression in prostate, prostate cancer or in metastatic prostate cancer samples. Second, RNAi based cell viability assay was performed in VCaP and LNCaP prostate cancer cells. Based on the siRNA results, gene expression patterns in human tissues and novelty, endoplasmic reticulum function associated targets AIM1, ERGIC1 and TMED3, as well as mitosis regulating TPX2 were selected for further validation. AIM1, ERGIC1, and TPX2 were shown to be highly expressed especially in prostate cancer tissues, and high mRNA expression of ERGIC1 and TMED3 associated with AR and ERG oncogene expression. ERGIC1 silencing specifically regulated the proliferation of ERG oncogene positive prostate cancer cells and inhibited ERG mRNA expression in these cells, indicating that it is a potent drug target in ERG positive subgroup of prostate cancers. TPX2 expression associated with PSA failure and TPX2 silencing reduced PSA expression, indicating that TPX2 regulates androgen receptor mediated signaling. In conclusion, the combinatorial usage of microarray and RNAi techniques yielded in a large number of potential novel biomarkers and therapeutic targets, for future development of targeted and personalized approaches for prostate cancer management.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761906/pdf/?tool=EBI |
| spellingShingle | Paula Vainio John-Patrick Mpindi Pekka Kohonen Vidal Fey Tuomas Mirtti Kalle A Alanen Merja Perälä Olli Kallioniemi Kristiina Iljin High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS ONE |
| title | High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. |
| title_full | High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. |
| title_fullStr | High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. |
| title_full_unstemmed | High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. |
| title_short | High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. |
| title_sort | high throughput transcriptomic and rnai analysis identifies aim1 ergic1 tmed3 and tpx2 as potential drug targets in prostate cancer |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761906/pdf/?tool=EBI |
| work_keys_str_mv | AT paulavainio highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT johnpatrickmpindi highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT pekkakohonen highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT vidalfey highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT tuomasmirtti highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT kalleaalanen highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT merjaperala highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT ollikallioniemi highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer AT kristiinailjin highthroughputtranscriptomicandrnaianalysisidentifiesaim1ergic1tmed3andtpx2aspotentialdrugtargetsinprostatecancer |